Citreoviridin is a mycotoxin and potent inhibitor of mitochondrial ATPase. Citreoviridin inhibits soluble ATPase (KD = 4.1 µM), ADP-stimulated respiration in isolated rat liver mitochondria (KD = 0.15 µM), and ATP-driven reduction of NAD+ by succinate (KD = 2 µM). Citreoviridin has been used to target ectopic ATPase activity in cancer cells in order to modulate the metabolic activity associated with tumorigenesis.
| Molecular Weight | 402.48 |
| Formula | C23H30O6 |
| CAS Number | 25425-12-1 |
| Solubility (25°C) | DMSO 10 mM |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] John I Pitt, et al. A Concise History of Mycotoxin Research
[4] E M Gause, et al. Binding of citreoviridin to the beta subunit of the yeast F1-ATPase
| Related ATPase Products |
|---|
| Transdermal Peptide Disulfide
Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. |
| SPAI-1
SPAI-1 is a specific inhibitor for monovalent cation transporting ATPases. |
| Prilocaine acetate
Prilocaine acetate, an amino amide, is a Na/K-ATPase inhibitor. |
| Chamigrenol
Chamigrenol is a Na+/K+-ATPase inhibitor with an IC50 value of 15.9 μg/mL. |
| ZW290
ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
